Pacific Biosciences of California
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 days.
- Its last 4 Sell calls were followed by a 19% average decline over the next quarter.
- Recent price momentum is +9.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 17.3% of float.
- Analyst tilt is Hold.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 28.6% | Better than 30% |
| Operating margin | -348.5% | Better than 4% |
| Net margin | -341.5% | Better than 4% |
| Return on equity | -213.5% | Better than 3% |
| Return on invested capital | -57.4% | Better than 5% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 20.7% | Better than 97% |
| 6-month return | 33.6% | Better than 91% |
| 12-month return (ex latest month) | -5.0% | Better than 28% |
| Distance below 52-week high | 52.5% | Better than 17% |
Financial Health D
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 5.1x | Better than 87% |
| Debt to assets | 89.6% | Better than 2% |
| Interest coverage | -77.5x | Better than 6% |
| Free cash flow / net income | 62.8% | Better than 18% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 40.0% | Better than 21% |
| Upside to average target | 62.0% | Better than 73% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 1.76
- Open
- 1.69
- Day range
- 1.61 - 1.73
- Avg price
- 1.66
- Volume
- 13.69M
- Turnover
- 22.75M
- Turnover ratei
- 4.47%
- Volume ratioi
- 0.98
- Amplitudei
- 6.82%
- 52-week rangei
- 1.07 - 3.44
Valuation
- P/Ei
- -0.90
- P/E (TTM)i
- -3.88
- P/Bi
- -8.32
- EPSi
- -1.82
- Book value / shi
- -0.20
- Net profit
- -569.53M
- Net assets
- -61.33M
Share structure
- Market cap
- 510.07M
- Float capi
- 499.22M
- Shares out
- 312.93M
- Float sharesi
- 306.27M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- --
52.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-15.01M net over the window
Short interest
- Shares short
- 53.68M
- % of floati
- 17.27%
- Days to coveri
- 4.14
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Pacific Biosciences of California (PACB)?
Pacific Biosciences of California last traded at 1.63. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Pacific Biosciences of California's market cap?
About 510.07M.
What is the P/E ratio of Pacific Biosciences of California?
The trailing twelve-month P/E is -3.88. The Valuation tab shows it against the stock's own five-year range.
Does Pacific Biosciences of California pay a dividend?
Pacific Biosciences of California does not currently pay a regular dividend.
Is Pacific Biosciences of California a buy according to analysts?
The consensus of 5 analysts is a Hold rating, with an average 12-month price target of 2.64, which implies 62.0% upside from the current price. This is not investment advice.
What is Pacific Biosciences of California's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Pacific Biosciences of California a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:52:58 · For reference only, not investment advice and not tailored to your situation.
Pacific Biosciences of California discussion 0 comments